Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-24-078056
Filing Date
2024-07-05
Accepted
2024-07-05 14:17:24
Documents
1
Group Members
JOSHUA LANDESNELSON OBUSWYNNEFIELD CAPITAL MANAGEMENT, LLCWYNNEFIELD CAPITAL, INC.WYNNEFIELD CAPITAL, INC. PROFIT SHARING PLANWYNNEFIELD PARTNERS SMALL CAP VALUE, L.PWYNNEFIELD SMALL CAP VALUE OFFSHORE FUND, LTD.

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm2418980d1_sc13da.htm SC 13D/A 146200
  Complete submission text file 0001104659-24-078056.txt   148197
Mailing Address 3515 LYMAN BOULEVARD CHASKA MN 55318
Business Address 3515 LYMAN BOULEVARD CHASKA MN 55318 9523684300
LIFECORE BIOMEDICAL, INC. \DE\ (Subject) CIK: 0001005286 (see all company filings)

EIN.: 943025618 | State of Incorp.: DE | Fiscal Year End: 0528
Type: SC 13D/A | Act: 34 | File No.: 005-45181 | Film No.: 241102388
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 450 SEVENTH AVENUE SUITE 509 NEW YORK NY 10123
Business Address 450 SEVENTH AVENUE SUITE 509 NEW YORK NY 10123 212-760-0814
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I (Filed by) CIK: 0001251565 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A